GHENT, Belgium, 7 January 2015 - Ablynx [Euronext Brussels: ABLX] today announced that its CEO, Dr Edwin Moses, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday 15 January 2015 at 10:30 a.m. Pacific Standard Time (07:30 p.m. Central Eastern Time).
The presentation will be webcast live and can be accessed on the day via this link:
http://jpmorgan.metameetings.com/confbook/healthcare15/directlink.php?p=17257 or on the homepage of the Ablynx website at www.ablynx.com:
http://www.ablynx.com. A replay of the webcast will be available for 30 days on the Company's website, under news & events, past events & presentations:
http://www.ablynx.com/en/news-press/past-events-presentations/. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
About Ablynx
Ablynx:
http://www.ablynx.com/ is a biopharmaceutical company engaged in the development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes:
http://www.ablynx.com/en/research-development/pipeline/ in development in therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations and significant partnerships with pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com:
http://www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com:
mailto:marieke.vermeersch@ablynx.com%20
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com:
mailto:ablynx@consilium-comms.com
http://hugin.info/137912/R/1884754/665942.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire